China's First-Ever Invasive Brain-Computer Interface Product Approval
China has approved its inaugural invasive brain-computer interface (BCI) product, marking a significant regulatory milestone in the field. This move positions Chinese startups to potentially compete with U.S. counterparts like Neuralink Corp., backed by Elon Musk, in the advanced tech industry.
Product Details and Approval
- Purpose: For adult patients partially paralyzed due to spinal cord injury.
- Capabilities: In clinical trials, the product improved patients' ability to hold and grab objects with their hands.
- Product System: Includes brain sensors, a robotic glove, surgical tools, brain signal decoding algorithm, medical testing software, and clinical management software.
- Limitations: Cleared only for those with some upper arm function. The implant has fewer signal-detection channels and is placed outside the brain's outer membrane.
Government Support and Industry Impact
- Strategic Importance: BCI is one of six strategic industries highlighted in China's latest five-year plan.
- Government Goals: To foster world-leading companies by the decade's end, streamline regulatory reviews, and establish reimbursement guidelines.
- Market Reaction: Approval spurred a stock rally among BCI-related companies in Hong Kong, with significant gains reported by Sanbo Hospital Management Group Ltd., Innovation Medical Management Co., and Nanjing Panda Electronics Co.
This development underscores China’s commitment to advancing in the BCI field and reflects growing global investment and interest in brain-related technologies.
